Thursday, October 30, 2014

SciBX: Science-Business eXchange Contents: October 30 2014, Volume 7 / Issue 42

If you are unable to see the message below, click here to view.
SciBX: Science-Business eXchange

Advertisement
Biopharma Dealmakers
A supplement to Nature Biotechnology and Nature Reviews Drug Discovery

The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Kymab Ltd.
 

TABLE OF CONTENTS

October 30 2014, Volume 7 / Issue 42

Analysis

Cover Story
Translational Notes
Tools

The Distillery: Therapeutics

Cancer
Cardiovascular disease
Endocrine/metabolic disease
Infectious disease
Inflammation
Musculoskeletal disease
Neurology
Various

The Distillery: Techniques

Assays and screens
Disease models
Drug platforms
Advertisement
Biopharma Dealmakers
A supplement to Nature Biotechnology and Nature Reviews Drug Discovery

The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with PlantForm Corporation


 

Analysis

Cover Story

Top

Redistributing BRD4 in inflammation
Kai-Jye Lou
doi:10.1038/scibx.2014.1223
A new link between inflammation and atherosclerosis centers on the BET bromodomain protein BRD4 and could provide new targets for intervention.
Full Text | PDF

Translational Notes

Top

The ALS bucket brigade
Benjamin Boettner
doi:10.1038/scibx.2014.1224
The ALS Association is allocating the first funds from its ice bucket challenge to create four new research alliances that focus on genetics and biomarkers for the disease.
Full Text | PDF

Bayer's Bay Area formula
Stephen Parmley
doi:10.1038/scibx.2014.1225
Bayer is emphasizing alliances rather than money to tap into Bay Area innovation.
Full Text | PDF

Tools

Top

Sex matters at the NIH
Lauren Martz
doi:10.1038/scibx.2014.1226
The NIH is taking steps to make the inclusion of both sexes in preclinical studies a standard practice.
Full Text | PDF

Distillery: Therapeutics

Cancer

Top

HER2 (EGFR2; ErbB2; neu); Erbb2 interacting protein (ERBB2IP; ERBIN)
doi:10.1038/scibx.2014.1227
Cell-based, primary tumor and mouse studies suggest inhibiting ERBIN could help treat HER2-driven luminal breast cancers.
Full Text | PDF

Mdm2 p53 binding protein homolog (MDM2; HDM2); p53
doi:10.1038/scibx.2014.1228
Mouse and in vitro studies have identified an MDM2 inhibitor that could help treat breast cancers regardless of p53 status.
Full Text | PDF

MicroRNA-100 (miR-100)
doi:10.1038/scibx.2014.1229
Cell-based, primary tumor and mouse studies suggest promoting miR-100 expression could help treat breast cancer.
Full Text | PDF

Not applicable
doi:10.1038/scibx.2014.1230
In vitro studies suggest an osmium(VI) nitrido complex targeting cancer stem cells (CSCs) could help treat breast cancer.
Full Text | PDF

AXL receptor tyrosine kinase (AXL; UFO); growth arrest–specific 6 (GAS6)
doi:10.1038/scibx.2014.1231
In vitro and mouse studies suggest an AXL-Fc fusion protein could help prevent cancer metastasis.
Full Text | PDF

Programmed cell death 1 (PDCD1; PD-1; CD279); programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274)
doi:10.1038/scibx.2014.1232
Mouse studies suggest combining radiotherapy with inhibitors of PD-1 or PD-L1 could help treat cancer.
Full Text | PDF

Zinc finger CCCH-type antiviral 1 (ZC3HAV1; ZAP)
doi:10.1038/scibx.2014.1233
In vitro and mouse studies suggest an oncolytic alphavirus could help treat cancers expressing low levels of ZAP.
Full Text | PDF

Cardiovascular disease

Top

Purkinje cell protein 4 (PCP4)
doi:10.1038/scibx.2014.1234
Mouse studies suggest agonizing PCP4 could help treat arrhythmia.
Full Text | PDF

Endocrine/metabolic disease

Top

Not applicable
doi:10.1038/scibx.2014.1235
Mouse studies suggest the mitochondria-targeted coenzyme Q10 analog mitoquinone could help treat obesity.
Full Text | PDF

Infectious disease

Top

Enterococcus faecalis endocarditis and biofilm-associated pilus subunit A (ebpA)
doi:10.1038/scibx.2014.1236
In vitro and mouse studies suggest an ebpA-based vaccine could help prevent catheter-associated urinary tract infection (CAUTI) caused by E. faecalis.
Full Text | PDF

Not applicable
doi:10.1038/scibx.2014.1237
Cell culture and mouse studies suggest Streptococcus pneumoniae capsular polysaccharides conjugated to the lipid antigen α-galactosylceramide (αGC) could help protect against S. pneumoniae infection.
Full Text | PDF

Inflammation

Top

CXC chemokine receptor 1 (CXCR1); CXCR2 (IL8RB)
doi:10.1038/scibx.2014.1238
In vitro and mouse studies suggest a new class of dual CXCR1 and CXCR2 inhibitors could help treat inflammatory diseases.
Full Text | PDF

Musculoskeletal disease

Top

SMAD family member 1 (MADH1; SMAD1) MADH5 (SMAD5); MADH9 (SMAD9; SMAD8)
doi:10.1038/scibx.2014.1239
Mouse studies suggest promoting ATP hydrolysis or inhibiting SMAD1, SMAD5 and SMAD8 could help treat injury-associated heterotopic ossification (HO).
Full Text | PDF

Wingless-type MMTV integration site family member 16B (WNT16B)
doi:10.1038/scibx.2014.1240
Rodent studies suggest WNT16B could help prevent bone loss and consequent bone fractures.
Full Text | PDF

Neurology

Top

Legumain (LGMN; AEP); microtubule-associated protein-τ (MAPT; tau; FTDP-17)
doi:10.1038/scibx.2014.1241
In vitro, patient sample and mouse studies suggest inhibiting AEP could help treat AD.
Full Text | PDF

Progranulin (PGRN; PCDGF)
doi:10.1038/scibx.2014.1242
Mouse studies suggest increasing PGRN levels in the brain could help treat AD.
Full Text | PDF

Not applicable
doi:10.1038/scibx.2014.1243
In vitro and rodent studies suggest analogs of octanoic acid could help treat epilepsy.
Full Text | PDF

High mobility group box 1 (HMGB1); HMGB2
doi:10.1038/scibx.2014.1244
Cell culture and mouse studies have identified a small molecule called inflachromene that could help treat neuroinflammation.
Full Text | PDF

κ-opioid receptor (OPRK1; KOR)
doi:10.1038/scibx.2014.1245
Mouse studies suggest the G protein–biased KOR agonists could help treat pain with fewer side effects than other classes of KOR agonists.
Full Text | PDF

Various

Top

Unknown
doi:10.1038/scibx.2014.1246
Mouse and flatworm studies have identified sulfido-conjugated compounds in human milk that could help promote tissue repair following infection or ischemia.
Full Text | PDF

Distillery: Techniques

Assays and screens

Top

Aptamer-mediated detection of low-epitope targets using organic receptor derivatization agents
doi:10.1038/scibx.2014.1247
In vitro studies suggest aptamer-mediated detection of low-epitope molecules such as monosaccharides could help diagnostics development.
Full Text | PDF

Cellular thermal shift assay (CETSA) to identify drug targets
doi:10.1038/scibx.2014.1248
A CETSA that detects ligand binding could help check for off-target binding and identify biomarkers during drug development.
Full Text | PDF

Genome-scale modulation of transcription with clustered, regularly interspaced short palindromic repeats (CRISPR)-Cas9 genome editing
doi:10.1038/scibx.2014.1249
Genome-scale modulation of transcription with CRISPR-Cas9 genome editing could help identify gene and gene transcript functions.
Full Text | PDF

Disease models

Top

Disease models generated by clustered, regularly interspaced short palindromic repeats (CRISPR) genome editing in transgenic Cas9–expressing mice
doi:10.1038/scibx.2014.1250
CRISPR-Cas9 genome editing could be used to generate mouse models of cancer and other diseases.
Full Text | PDF

Drug platforms

Top

In vitro generation of insulin-producing cells from human pluripotent stem cells to treat type 1 diabetes
doi:10.1038/scibx.2014.1251
An in vitro protocol to generate insulin-producing cells from human pluripotent stem cells could be useful for developing cellular therapies to treat type 1 diabetes.
Full Text | PDF

Top

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: